Top

Published in:

01-08-2019 | Prostate Cancer | News item

No increased risk of prostate cancer with entacapone

Published in: Reactions Weekly | Issue 1/2019

Excerpt

A review of additional data in the US indicates that the Parkinson's disease therapy entacapone is not associated with an increased risk of prostate cancer, says the US FDA. …

STRIDE-PD = Stalevo Reduction In Dyskinesia Evaluation − Parkinson's Disease

see Reactions 1297 p2; 801075618

US Food and Drug Administration. FDA review finds no increased risk of prostate cancer with Parkinson's disease medicines containing entacapone (Comtan, Stalevo). Internet Document : 13 Aug 2019. Available from: URL: https://www.fda.gov/drugs/drug-safety-and-availability/fda-review-finds-no-increased-risk-prostate-cancer-parkinsons-disease-medicines-containing

Title: No increased risk of prostate cancer with entacapone
Publication date: 01-08-2019
Publisher: Springer International Publishing
Keywords: Prostate Cancer
Prostate Cancer
Parkinson's Disease
Carbidopa
Levodopa
Entacapone
Published in: Reactions Weekly / Issue 1/2019
Print ISSN: 0114-9954
Electronic ISSN: 1179-2051
DOI: https://doi.org/10.1007/s40278-019-66373-y

At a glance: The STEP trials

Springer Medicine

No increased risk of prostate cancer with entacapone

Excerpt

At a glance: The STEP trials

Springer Medicine

Excerpt

Please log in to get access to this content

Other articles of this Issue 1/2019

Mycophenolate mofetil/prednisolone/tacrolimus

Gefitinib/osimertinib

Mycophenolate mofetil

Antineoplastics

Dasatinib

Multiple drugs